Patents Assigned to The University of Alabama Research Foundation
  • Patent number: 7820784
    Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides comprise class A amphiphathic helices, are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: October 26, 2010
    Assignees: The Regents of the University of California, The University of Alabama Research Foundation
    Inventors: Alan M. Fogelman, Gattadahalli M. Anantharamaiah, Mohamad Navab
  • Publication number: 20100143414
    Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?3) ribitol (5?phosphate}. This new serotype may be included in pneumococcal vaccines.
    Type: Application
    Filed: December 28, 2006
    Publication date: June 10, 2010
    Applicant: THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION
    Inventors: Moon H. Nahm, Jisheng Lin, Angela P. Brandao, Maria Cristina Brandileone
  • Publication number: 20090170162
    Abstract: The embodiments described herein provide for immunogenic portions of Streptococcus pneumoniae surface protein A and surface protein C lacking alpha helical structure.
    Type: Application
    Filed: February 1, 2007
    Publication date: July 2, 2009
    Applicant: THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION
    Inventors: Susan K. Hollingshead, David E. Briles
  • Publication number: 20090162384
    Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.
    Type: Application
    Filed: September 6, 2007
    Publication date: June 25, 2009
    Applicants: DUKE UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION AT BIRMINGHAM
    Inventor: Barton F. Haynes
  • Publication number: 20080096816
    Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.
    Type: Application
    Filed: July 30, 2007
    Publication date: April 24, 2008
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION
    Inventors: Alan Fogelman, Gattadahalli Anantharamaiah, Mohamad Navab
  • Publication number: 20080096815
    Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.
    Type: Application
    Filed: July 30, 2007
    Publication date: April 24, 2008
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION
    Inventors: Alan Fogelman, Gattadahalli Anantharamaiah, Mohamad Navab
  • Publication number: 20080096814
    Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.
    Type: Application
    Filed: July 30, 2007
    Publication date: April 24, 2008
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION
    Inventors: Alan Fogelman, Gattadahalli Anantharamaiah, Mohamad Navab
  • Publication number: 20070154569
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Application
    Filed: July 9, 2004
    Publication date: July 5, 2007
    Applicants: The Govt. of the U.S.A. through The Dept. of Health and Human Services, The University of Alabama Research Foundation, Wake Forest University, Loma Linda University, The Board of Supervisors of Louisiana State University
    Inventors: Mark Gladwin, Alan Schechter, David Lefer, Rakesh Patel, Christian Hunter, Gordon Power, Daniel Kim-Shapiro, Ryszard Pluta, Edward Oldfield, Richard Cannon
  • Patent number: 7166578
    Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages. In certain embodiments, the peptides range in length from about 10 up to about 30 amino acids, comprise at least one class A amphipathic helix, and protect a phospholipid against oxidation by an oxidizing agent.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: January 23, 2007
    Assignees: The Regents of the University of California, The University of Alabama Research Foundation
    Inventors: Alan M Fogelman, Gattadahalli M Anantharamaiah, Mohamad Navab
  • Patent number: 7148197
    Abstract: This invention provides novel peptides for the treatment of atherosclerosis.
    Type: Grant
    Filed: August 26, 2003
    Date of Patent: December 12, 2006
    Assignees: The Regents of the University of California, The University of Alabama Research Foundation
    Inventors: Alan M Fogelman, Gattadahalli M Anantharamaiah, Mohamad Navab
  • Patent number: 7144862
    Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. In certain embodiments, the peptide comprises an amino acid sequence that ranges in length from about 10 up to about 30 amino acids, that comprises at least one class A amphipathic helix, that bears at least one protecting group, that protects a phospholipid against oxidation by an oxidizing agent; and that is not the D-18A peptide. The peptides are highly stable and readily administered via an oral route.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: December 5, 2006
    Assignees: The Regents of the University of California, The University of Alabama Research Foundation
    Inventors: Alan M. Fogelman, Gattadahalli M. Anantharamaiah, Mohamad Navab
  • Patent number: 6680169
    Abstract: The invention pertains to methods of delivering a polypeptide to a cell comprising (a) contacting a cell with a replicon having a non-poliovirus nucleic acid substituted for a nucleic acid which encodes at least a portion of a protein necessary for encapsidation, the non-poliovirus nucleic acid encoding, in an expressible form, a polypeptide or fragment thereof; and (b) maintaining the cells under conditions appropriate for introduction of the replicons into the cells. The cell may be within a subject and the polypeptide may be a therapeutic agent. The methods of the invention may be used to treat diseases including central nervous system disorders, infectious diseases, and cancer.
    Type: Grant
    Filed: April 16, 2001
    Date of Patent: January 20, 2004
    Assignee: University of Alabama Research Foundation
    Inventors: Casey D. Morrow, Cheryl Jackson, Jean Peduzzi
  • Publication number: 20030166563
    Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.
    Type: Application
    Filed: March 20, 2003
    Publication date: September 4, 2003
    Applicant: University of Alabama Research Foundation
    Inventors: John C. Kappes, Xiaoyun Wu
  • Patent number: 6525033
    Abstract: A method for treating HBV infections via administration of 2′, 3′ dideoxynucleoside compounds.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: February 25, 2003
    Assignees: Emory University, University of Alabama Research Foundation, Inc.
    Inventors: Raymond F. Schinazi, Jean-Pierre Sommadossi, Gilles Gosselin, Jean-Louis Imbach
  • Patent number: 6500852
    Abstract: The present invention provides methods of synthesizing and screening inhibitors of bacterial NAD synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial NAD synthetase enzyme.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: December 31, 2002
    Assignee: University of Alabama Research Foundation
    Inventors: Wayne J. Brouillette, Donald Muccio, Mark J. Jedrzejas, Christie G. Brouillette, Yancho Devedjiev, Walter Cristofoli, Lawrence J. DeLucas, Jose Gabriel Garcia, Laurent Schmitt, Sadanandan E. Velu
  • Patent number: 6362000
    Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: March 26, 2002
    Assignee: University of Alabama Research Foundation
    Inventors: John Christopher Kappes, Xiaoyun Wu
  • Patent number: 6090609
    Abstract: The matrix protein, M1, of influenza virus strain A/PR/8/34 has been purified from virions and crystallized. The crystals consist of a stable fragment (18 Kd) of the M1 protein. X-ray diffraction studies indicated that the crystals have a space group of P3.sub.t 21 or P3.sub.2 21. Vm calculations showed that there are two monomers in an asymmetric unit. A crystallized N-terminal domain of M1, wherein the N-terminal domain of M1 is crystallized such that the three dimensional structure of the crystallized N-terminal domain of M1 can be determined to a resolution of about 2.1 .ANG. or better, and wherein the three dimensional structure of the uncrystallized N-terminal domain of M1 cannot be determined to a resolution of about 2.1 .ANG. or better. A method of purifying M1 and a method of crystallizing M1. A method of using the three-dimensional crystal structure of M1 to screen for antiviral, influenza virus treating or preventing compounds.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: July 18, 2000
    Assignee: University of Alabama Research Foundation
    Inventors: Ming Luo, Bingdong Sha
  • Patent number: 6017896
    Abstract: The present invention provides a method of killing replicating or non-replicating, transfected or transduced mammalian cells and bystander cells, comprising: (a) transfecting or transducing mammalian cells with a nucleic acid encoding a non-human purine cleavage enzyme; and (b) contacting the transfected or transduced cells with an effective amount of a substrate for the purine cleavage enzyme, wherein the substrate is non-toxic to mammalian cells and is cleaved by the enzyme to yield a purine toxic to the targeted mammalian cells and bystander cells, to kill the mammalian cells expressing the enzyme and the bystander cells. Further provided is a vector comprising a DNA sequence coding for a non-human purine nucleoside phosphorylase protein and the vector is capable of replication and/or expression in a host which comprises, in operable linkage: a) optionally, an origin of replication; b) a promoter; and c) a DNA sequence coding for said protein.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: January 25, 2000
    Assignee: University of Alabama Research Foundation and Southern Research Institute
    Inventors: Eric J. Sorscher, Leonard L. Bennett, Jr., William B. Parker
  • Patent number: 6001985
    Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a virus inhibitory protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a virus inhibitory protein. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: December 14, 1999
    Assignee: University of Alabama Research Foundation
    Inventors: John Christopher Kappes, Xiaoyun Wu
  • Patent number: 5990093
    Abstract: A method for treating HBV infections comprising administering a 5'-phospholipid prodrug of .beta.-L-2',3'-dideoxyadenosine 5'-monophosphate.
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: November 23, 1999
    Assignees: Emory University, University of Alabama Research Foundation, Inc., CNRS
    Inventors: Raymond F. Schinazi, Jean-Pierre Sommadossi, Gilles Gosselin, Jean-Louis Imbach